Mitochondria-derived peptides including humanin, MOTS-c, and SHLPs protect liver cells, regulate metabolism, and show therapeutic potential for fatty liver disease and fibrosis.
3 peptide families from mitochondrial DNAHumanin, MOTS-c, and SHLPs represent a novel paradigm where mitochondria actively produce signaling peptides that protect liver cells and regulate metabolism
What the researchers found
The review identifies three key mitochondria-derived peptide (MDP) families and their roles in liver health:
- Humanin: The first discovered MDP; protects hepatocytes from stress-induced cell death (apoptosis) and modulates lipid metabolism, exerting hepatoprotective effects in fatty liver disease
- MOTS-c: Activates AMPK (a master metabolic regulator), regulates nuclear gene expression, suppresses fibrotic and inflammatory signaling, and restores mitochondrial function in MASLD and fibrosis models
- SHLPs (1-6): Particularly SHLP2, which enhances mitochondrial function, improves insulin sensitivity, supports glucose homeostasis, and mitigates oxidative stress
MDPs work both inside cells (modulating mitochondrial activity, oxidative stress, apoptosis) and outside cells (autocrine, paracrine, endocrine signaling), establishing a novel paradigm where mitochondrial DNA function extends well beyond energy production.
Why it matters
Fatty liver disease (MASLD) affects about 30% of the global population and has limited treatment options. Mitochondrial dysfunction is central to its progression. Discovering that mitochondria produce their own protective peptides opens an entirely new therapeutic avenue — potentially treating liver disease by supplementing or enhancing the body's own mitochondrial defense system.
How the study worked
This is a narrative review published in Hepatology Communications synthesizing current research on mitochondria-derived peptides, their biological mechanisms, and their relevance to chronic liver diseases, particularly metabolic dysfunction-associated steatotic liver disease (MASLD).
What this study cannot tell us
Most evidence for MDPs in liver disease comes from cell culture and animal models; human clinical data is very limited. The exact receptors and signaling pathways for many MDPs are still being identified. Therapeutic development faces challenges including peptide stability, delivery, and determining effective doses in humans. Interactions between different MDPs are not well understood.
How to read the evidence
This is a narrative review synthesizing primarily preclinical evidence. While the mechanistic data is compelling, most findings come from cell and animal models with limited clinical validation for liver-specific applications.
When this study was published
Published in 2026, this is a very current review capturing the latest understanding of mitochondria-derived peptides in liver disease, a rapidly emerging field.
The bigger picture
Mitochondria-derived peptides represent a paradigm shift in our understanding of mitochondrial biology. These organelles were long thought to simply produce energy, but the discovery that they encode bioactive signaling peptides reveals them as active regulators of cellular health, metabolism, and inter-organ communication — with implications extending beyond the liver to aging, diabetes, and neurodegeneration.
Questions still open
- Could circulating MDP levels serve as biomarkers for fatty liver disease severity?
- Would exogenous MOTS-c or humanin administration be effective and safe in human MASLD patients?
- How do MDP levels change with aging, and does this contribute to age-related liver disease?
Common questions
What are mitochondria-derived peptides?
Could these peptides treat fatty liver disease?
Read the original research
Mitochondria-derived peptides in liver disease: Emerging regulators of hepatic metabolism and therapeutic targets.
Hepatology communications, 10(2)
Citation
Thoudam, Themis; Zeng, Ge; Gao, Hui; Jiang, Yanchao; Huda, Nazmul; Yang, Zhihong; Ma, Jing; Liangpunsakul, Suthat. (2026). Mitochondria-derived peptides in liver disease: Emerging regulators of hepatic metabolism and therapeutic targets.. Hepatology communications, 10(2). https://doi.org/10.1097/HC9.0000000000000885